A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies

[1] Huijgen R(2010)Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal PLoS One 5 e9220-2445

[2] Kindt I(2005)High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2437-734

[3] Verhoeven SB(2008)Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 337 a2423-67

[4] Sijbrands EJ(2010)Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Value Health. 13 726-281

[5] Vissers MN(2011)Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia Neth Heart J. 19 61-535

[6] Kastelein JJ(2012)Principles of health economic evaluations of lipid-lowering strategies Curr Opin Lipidol 23 271-336

[7] Pedersen TR(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med. 6 e1000100-317

[8] Faergeman O(2004)An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK Pharmacoeconomics. 22 525-1582

[9] Kastelein JJ(2004)Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands Neth Heart J. 12 331-268

[10] Olsson AG(2006)The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention Cardiovasc Drugs Ther 20 309-1007

[1] Huijgen R(2010)Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal PLoS One 5 e9220-2445

[2] Kindt I(2005)High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2437-734

[3] Verhoeven SB(2008)Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 337 a2423-67

[4] Sijbrands EJ(2010)Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Value Health. 13 726-281

[5] Vissers MN(2011)Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia Neth Heart J. 19 61-535

[6] Kastelein JJ(2012)Principles of health economic evaluations of lipid-lowering strategies Curr Opin Lipidol 23 271-336

[7] Pedersen TR(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med. 6 e1000100-317

[8] Faergeman O(2004)An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK Pharmacoeconomics. 22 525-1582

[9] Kastelein JJ(2004)Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands Neth Heart J. 12 331-268

[10] Olsson AG(2006)The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention Cardiovasc Drugs Ther 20 309-1007